Genome-wide Association Study Identifies 2 New Loci Associated With Anti-NMDAR Encephalitis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received March 16, 2021
- Accepted in final form July 9, 2021
- First Published September 28, 2021.
Author Disclosures
- Anja K. Tietz, MSc (anja.tietz{at}uksh.de),
- Klemens Angstwurm, MD (klemens.angstwurm{at}medbo.de),
- Tobias Baumgartner, MD (tobias.baumgartner{at}ukbonn.de),
- Kathrin Doppler, MD (doppler_k{at}ukw.de),
- Katharina Eisenhut, MD (katharina.eisenhut{at}med.uni-muenchen.de),
- Martin Elisak, MD (martin.elisak{at}gmail.com),
- Andre Franke, PhD (a.franke{at}mucosa.de),
- Kristin S. Golombeck, MD (kristin.golombeck{at}ukmuenster.de),
- Robert Handreka (r.handreka{at}ctk.de),
- Max Kaufmann, MD (m.kaufmann{at}uke.de),
- Markus Kraemer, MD (markus.kraemer{at}krupp-krankenhaus.de),
- Andrea Kraft, MD (andrea.kraft{at}martha-maria.de),
- Jan Lewerenz, MD (jan.lewerenz{at}googlemail.com),
- Wolfgang Lieb, MD (wolfgang.lieb{at}epi.uni-kiel.de),
- Marie Madlener, MD (marie.madlener{at}uk-koeln.de),
- Nico Melzer, MD (nico.melzer{at}med.uni-duesseldorf.de),
- Hana Mojzisova, MD (hana.mojzisova{at}gmail.com),
- Peter Möller, MD (p.moeller{at}klinikum-weimar.de),
- Thomas Pfefferkorn, MD (thomas.pfefferkorn{at}klinikum-ingolstadt.de),
- Harald Prüss, MD (harald.pruess{at}charite.de),
- Kevin Rostásy, MD (k.rostasy{at}kinderklinik-datteln.de),
- Margret Schnegelsberg, MD (m.schnegelsberg{at}asklepios.com),
- Ina Schröder (ina.schroeder{at}uksh.de),
- Kai Siebenbrodt, MD (kai.siebenbrodt{at}kgu.de),
- Kurt-Wolfram Sühs, MD (suehs.kurt-wolfram{at}mh-hannover.de),
- Jonathan Wickel, MD (jonathan.wickel{at}med.uni-jena.de),
- Klaus-Peter Wandinger, MD (klaus-peter.wandinger{at}uksh.de),
- Frank Leypoldt, MD (frank.leypoldt{at}uksh.de),
- Gregor Kuhlenbäumer, MD, PhD;
- on behalf of the German Network for Research on Autoimmune Encephalitis (GENERATE)
- Anja K. Tietz, MSc (anja.tietz{at}uksh.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Federal Ministry of Education and Research (BMBF), grant code 01GM1908A, within the scope of the project CONNECT-GENERATE, 2019-2022
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Klemens Angstwurm, MD (klemens.angstwurm{at}medbo.de),
NONE
NONE
commercial entity, travel funding by Alexion, Bayer, BiogenIdec, MerckSerono,Novartis, and Teva in 2009 upto 2014; honoraria by BiogenIdec.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Commercial entity: clinical studies on NMOSD for Alexion and Chugai, clinical studies on multiple sclerosis for Bayer, BiogenIdec, MerckSerono, Novartis, and Roche.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tobias Baumgartner, MD (tobias.baumgartner{at}ukbonn.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kathrin Doppler, MD (doppler_k{at}ukw.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)German Research Foundation, DO 2219/1-1, 2018-2021, DO 2219/2-1, 2021-2024 (2)Federal Ministry of Education and Research (BMBF), 2016-2019
NONE
(1)International Parkinson Fonds, 2018-2021
NONE
NONE
NONE
NONE
NONE
NONE
- Katharina Eisenhut, MD (katharina.eisenhut{at}med.uni-muenchen.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Martin Elisak, MD (martin.elisak{at}gmail.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Andre Franke, PhD (a.franke{at}mucosa.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kristin S. Golombeck, MD (kristin.golombeck{at}ukmuenster.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Robert Handreka (r.handreka{at}ctk.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Max Kaufmann, MD (m.kaufmann{at}uke.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Stifterverband (2) German Research Foundation (DFG)
NONE
NONE
NONE
NONE
NONE
NONE
- Markus Kraemer, MD (markus.kraemer{at}krupp-krankenhaus.de),
MK received honoraria for educational activities from Roche Pharma and Chugai Pharma.
NONE
Markus Kraemer received honoriaria for educational activities from Roche Pharma and Chugai Pharma.
Associate Editor of German DGNeurologie Journal.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Andrea Kraft, MD (andrea.kraft{at}martha-maria.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jan Lewerenz, MD (jan.lewerenz{at}googlemail.com),
NONE
NONE
1. UCB, travel compensation 2. Bayer, speaker fees 3. Roche, travel compensation 4. Teva, speakers fees 5. the Cure HuntingtonÂs Disease Initiative (CHDI), travel compensation
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Laboratory for cerebrospinal fluid analysis and clinical neurochemistry, CSF studies including pathogen-specific antibody testing, testing for antineuronal antibodies, 10%, 10 years
UCB
1. German Federal Ministry of Education and Research (BMBF), grant codes 01GM1908A and 01GM1908C 2. Ministry for Education and Research Baden-Württemberg, 33-7533-6-21/9/1_U1
NONE
European HuntingtonÂs Disease Network
NONE
NONE
NONE
NONE
NONE
NONE
- Wolfgang Lieb, MD (wolfgang.lieb{at}epi.uni-kiel.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marie Madlener, MD (marie.madlener{at}uk-koeln.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Nico Melzer, MD (nico.melzer{at}med.uni-duesseldorf.de),
1. Commercial Advisory Board, Alexion Pharmaceuticals, Germany
NONE
1. Biogen Idec, honoraria for lecturing and travel expenses for attending meetings 2. GlaxoSmith Kline, honoraria for lecturing and travel expenses for attending meetings 3. Teva, honoraria for lecturing and travel expenses for attending meetings 4. Fresenius Medical Care, honoraria for lecturing and travel expenses for attending Meetings 5. Alexion Pharmaceuticals Germany, honoraria for lecturing and travel expenses for attending Meetings
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1. Immunoadsorption, (5%), 3 years
1. Fresenius Medical Care 2. Diamed 3. Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hana Mojzisova, MD (hana.mojzisova{at}gmail.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Grant Agency Charles University Czech republic, grant no 746120, main investigator, 2020-2022
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Peter Möller, MD (p.moeller{at}klinikum-weimar.de),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Thomas Pfefferkorn, MD (thomas.pfefferkorn{at}klinikum-ingolstadt.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Harald Prüss, MD (harald.pruess{at}charite.de),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Kevin Rostásy, MD (k.rostasy{at}kinderklinik-datteln.de),
Scientific adviser on Fingolimod project-Novartis
NONE
Advisory Board Meeting Novartis and Merck 2017, 2018
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Margret Schnegelsberg, MD (m.schnegelsberg{at}asklepios.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ina Schröder (ina.schroeder{at}uksh.de),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Kai Siebenbrodt, MD (kai.siebenbrodt{at}kgu.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kurt-Wolfram Sühs, MD (suehs.kurt-wolfram{at}mh-hannover.de),
(1)Merck(2)Biogen
NONE
(1) Merck funding for travel for conference(2) Biogen Advisory Board Member
NONE
NONE
NONE
Hannover Medical SchoolCarl-Neuberg-Stra?e 130625 GermanyDept. Neurology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Jonathan Wickel, MD (jonathan.wickel{at}med.uni-jena.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Klaus-Peter Wandinger, MD (klaus-peter.wandinger{at}uksh.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Frank Leypoldt, MD (frank.leypoldt{at}uksh.de),
(1) Roche (2) Biogen (3) Alexion (4) Novartis
NONE
(1) Grifols (2) Teva (3) Biogen (4) Fresenius (5) Bayer (6) Novartis (6) Roche (6) Novartis (7) Merck (8) Roche (9) Alexion
Neurology: Neuroimmunology and Neuroinflammation
NONE
NONE
NONE
NONE
NONE
NONE
Institute of Laboratory Medicine, University Hospital Schleswig- Holstein Campus Kiel, Germany, commercial antibody testing service, 20%
NONE
(1) German Ministry of Education and Research (BMBF) Speaker, PI 2019 01GM1908A (2) German Research Council (GRC, DFG), PI, 2019 LE 3064/2-1
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gregor Kuhlenbäumer, MD, PhD;
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Deutsche Forschungsgemeinschaft, grant KU1194/9-1, 2014-2019(2) Deutsche Forschungsgemeinschaft, grant KU1194/8-1, 2014-2019(3) BMBF, Connect-Generate, 01GM1908A
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- on behalf of the German Network for Research on Autoimmune Encephalitis (GENERATE)
- From the Department of Neurology (A.K.T., F.L., G.K.), Kiel University; Department of Neurology (K.A.), University Hospital Regensburg; Department of Epileptiology (T.B.), University Hospital Bonn; Department of Neurology (K.D.), University Hospital Würzburg; Institute of Clinical Neuroimmunology (K.E.), Biomedical Center and University Hospital, Ludwig Maximilians University, Munich, Germany; Department of Neurology (M.E., H.M.), Charles University, Second Faculty of Medicine and Motol University Hospital, Prague, Czech Republic; Institute of Clinical Molecular Biology (A.F.), Kiel University; Department of Neurology (K.S.G.), University Hospital Münster; Department of Neurology (R.H.), Carl-Thiem-Klinikum Cottbus; Institute of Neuroimmunology and Multiple Sclerosis (INIMS) (Max Kaufmann), University Medical Center Hamburg-Eppendorf; Department of Neurology (Markus Kraemer), Alfried Krupp Hospital, Essen; Department of Neurology (Markus Kraemer, N.M.), Medical Faculty, Heinrich-Heine University Düsseldorf; Department of Neurology (A.K.), Martha-Maria Hospital Halle; Department of Neurology (J.L.), University of Ulm; Institute of Epidemiology (W.L.), Kiel University; Department of Neurology (M.M.), University Hospital Cologne; Department of Neurology and Clinical Neurophysiology (P.M.), Klinikum Weimar; Department of Neurology (T.P.), Klinikum Ingolstadt; Department of Neurology and Experimental Neurology (H.P.), Charité - Universitätsmedizin Berlin and German Center for Neurodegenerative Diseases (DZNE) Berlin; Department of Pediatric Neurology (K.R.), Children's Hospital Datteln, Witten/Herdecke University; Department of Neurology (M.S.), Asklepios Hospitals Schildautal, Seesen; Neuroimmunology (I.S., K.-P.W., F.L.), Institute of Clinical Chemistry, University Hospital Schleswig-Holstein, Kiel/Lübeck; Epilepsy Center Frankfurt Rhine-Main and Department of Neurology (K.S.), Unversity Hospital and Goethe Universiy Frankfurt; Department of Neurology (K.-W.S.), Hannover Medical School; and Section Translational Neuroimmunology (J.W.), Department of Neurology, University Hospital Jena, Germany.
- Correspondence
Dr. Kuhlenbäumer g.kuhlenbaeumer{at}neurologie.uni-kiel.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.